Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $18.82 billion. The enterprise value is $22.71 billion.
| Market Cap | 18.82B |
| Enterprise Value | 22.71B |
Important Dates
The last earnings date was Thursday, May 1, 2025, before market open.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 146.53 million shares outstanding. The number of shares has increased by 0.21% in one year.
| Current Share Class | 146.53M |
| Shares Outstanding | 146.53M |
| Shares Change (YoY) | +0.21% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 89.78% |
| Float | 146.16M |
Valuation Ratios
The trailing PE ratio is 12.73 and the forward PE ratio is 8.15. Biogen's PEG ratio is 3.05.
| PE Ratio | 12.73 |
| Forward PE | 8.15 |
| PS Ratio | 1.87 |
| Forward PS | 2.01 |
| PB Ratio | 1.09 |
| P/TBV Ratio | 20.38 |
| P/FCF Ratio | 7.67 |
| P/OCF Ratio | 7.24 |
| PEG Ratio | 3.05 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.37, with an EV/FCF ratio of 9.32.
| EV / Earnings | 15.35 |
| EV / Sales | 2.31 |
| EV / EBITDA | 7.37 |
| EV / EBIT | 9.58 |
| EV / FCF | 9.32 |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.39.
| Current Ratio | 1.44 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 2.07 |
| Debt / FCF | 2.72 |
| Interest Coverage | 9.84 |
Financial Efficiency
Return on equity (ROE) is 9.19% and return on invested capital (ROIC) is 6.48%.
| Return on Equity (ROE) | 9.19% |
| Return on Assets (ROA) | 5.43% |
| Return on Invested Capital (ROIC) | 6.48% |
| Return on Capital Employed (ROCE) | 10.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.00 |
Taxes
In the past 12 months, Biogen has paid $273.10 million in taxes.
| Income Tax | 273.10M |
| Effective Tax Rate | 15.58% |
Stock Price Statistics
The stock price has decreased by -40.85% in the last 52 weeks. The beta is 0.12, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | -40.85% |
| 50-Day Moving Average | 125.85 |
| 200-Day Moving Average | 157.71 |
| Relative Strength Index (RSI) | 57.71 |
| Average Volume (20 Days) | 1,588,720 |
Short Selling Information
The latest short interest is 3.18 million, so 2.17% of the outstanding shares have been sold short.
| Short Interest | 3.18M |
| Short Previous Month | 3.45M |
| Short % of Shares Out | 2.17% |
| Short % of Float | 2.18% |
| Short Ratio (days to cover) | 1.77 |
Income Statement
In the last 12 months, Biogen had revenue of $9.82 billion and earned $1.48 billion in profits. Earnings per share was $10.12.
| Revenue | 9.82B |
| Gross Profit | 7.43B |
| Operating Income | 2.37B |
| Pretax Income | n/a |
| Net Income | 1.48B |
| EBITDA | 3.08B |
| EBIT | 2.37B |
| Earnings Per Share (EPS) | $10.12 |
Balance Sheet
The company has $2.60 billion in cash and $6.62 billion in debt, giving a net cash position of -$4.02 billion or -$27.45 per share.
| Cash & Cash Equivalents | 2.60B |
| Total Debt | 6.62B |
| Net Cash | -4.02B |
| Net Cash Per Share | -$27.45 |
| Equity (Book Value) | 16.98B |
| Book Value Per Share | 115.90 |
| Working Capital | 2.33B |
Cash Flow
In the last 12 months, operating cash flow was $2.58 billion and capital expenditures -$144.90 million, giving a free cash flow of $2.44 billion.
| Operating Cash Flow | 2.58B |
| Capital Expenditures | -144.90M |
| Free Cash Flow | 2.44B |
| FCF Per Share | $16.63 |
Margins
Gross margin is 75.65%, with operating and profit margins of 24.16% and 15.07%.
| Gross Margin | 75.65% |
| Operating Margin | 24.16% |
| Pretax Margin | 17.85% |
| Profit Margin | 15.07% |
| EBITDA Margin | 31.39% |
| EBIT Margin | 24.16% |
| FCF Margin | 24.82% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.21% |
| Shareholder Yield | -0.21% |
| Earnings Yield | 7.92% |
| FCF Yield | 13.04% |
Analyst Forecast
The average price target for Biogen is $194.95, which is 51.75% higher than the current price. The consensus rating is "Buy".
| Price Target | $194.95 |
| Price Target Difference | 51.75% |
| Analyst Consensus | Buy |
| Analyst Count | 26 |
| Revenue Growth Forecast (5Y) | 0.03% |
| EPS Growth Forecast (5Y) | 10.16% |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.17 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.17 |
| Piotroski F-Score | 6 |